Talphera (TLPH) Registration filing summary

Company overview and business model

• Specialty pharmaceutical developer focused on therapies for medically supervised settings; current resources are concentrated on Niyad, a regional anticoagulant for the dialysis circuit.

• Strategy centers on developing, obtaining approval for and commercializing Niyad, with plans to expand into additional acute-care therapies; LTX-608 may be pursued for DIC, ARDS, acute pancreatitis or antiviral use.

• Two pre-filled syringe product candidates have been explored and are under evaluation for discontinuation.

Financial performance and metrics

• BPM LLP’s audit report on FY2024–FY2025 consolidated financial statements includes an explanatory paragraph regarding ability to continue as a going concern.

• Smaller reporting company status reflects non-affiliate market value below $700 million and FY revenue below $100 million; reduced reporting requirements include two audited fiscal years and reduced executive-compensation disclosure.

Use of proceeds and capital allocation

• Net proceeds, if any, are intended for working capital and general corporate purposes, including commercialization, G&A, R&D, capex and scheduled debt-facility payments; supplements may specify other uses.